Bronchopulmonary Dysplasia - Epidemiology Forecast to 2032

January 2022 | 60 pages | ID: B5924F6DA3A9EN
DelveInsight

Abstracts

This report can be delivered to the clients within 5-7 Business Days

DelveInsight's 'Bronchopulmonary Dysplasia - Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Bronchopulmonary Dysplasia epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Geographies Covered

• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2019-2032

Bronchopulmonary Dysplasia Understanding

The DelveInsight Bronchopulmonary Dysplasia epidemiology report gives a thorough understanding of the Bronchopulmonary Dysplasia by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for Bronchopulmonary Dysplasia in the US, Europe, and Japan. The report covers the detailed information of the Bronchopulmonary Dysplasia epidemiology scenario in seven major countries (US, EU5, and Japan).

Bronchopulmonary Dysplasia Epidemiology Perspective by DelveInsight

The Bronchopulmonary Dysplasia epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The Bronchopulmonary Dysplasia epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. The Bronchopulmonary Dysplasia epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2019 to 2032. It also helps recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Bronchopulmonary Dysplasia Detailed Epidemiology Segmentation

The Bronchopulmonary Dysplasia epidemiology covered in the report provides historical as well as forecasted Bronchopulmonary Dysplasia epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.

The DelveInsight Bronchopulmonary Dysplasia report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

Scope of the Report

• The Bronchopulmonary Dysplasia report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
• The Bronchopulmonary Dysplasia Epidemiology Report and Model provide an overview of the global trends of Bronchopulmonary Dysplasia in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan)
• The report provides insight into the historical and forecasted patient pool of Bronchopulmonary Dysplasia in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
• The report helps recognize the growth opportunities in the 7MM for the patient population
• The report assesses the disease risk and burden and highlights the unmet needs of Bronchopulmonary Dysplasia
• The report provides the segmentation of the Bronchopulmonary Dysplasia epidemiology

Report Highlights

• 11-year Forecast of Bronchopulmonary Dysplasia epidemiology
• 7MM Coverage
• Prevalent and Diagnosed Cases of Bronchopulmonary Dysplasia
• Cases of Bronchopulmonary Dysplasia by Mutation Types
• Bronchopulmonary Dysplasia Cases associated with Clinical Manifestations

KOL views

We interview, KOLs and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered

• What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Bronchopulmonary Dysplasia?
• What are the key findings pertaining to the Bronchopulmonary Dysplasia epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2019-2032)?
• What would be the total number of patients of Bronchopulmonary Dysplasia across the 7MM during the forecast period (2019-2032)?
• Among the EU5 countries, which country will have the highest number of patients during the forecast period (2019-2032)?
• At what CAGR the patient population is expected to grow in 7MM during the forecast period (2019-2032)?
• What is the disease risk, burden and unmet needs of Bronchopulmonary Dysplasia?
• What are the currently available treatments of Bronchopulmonary Dysplasia?

Reasons to buy

The Bronchopulmonary Dysplasia Epidemiology report will allow the user to -

• Develop business strategies by understanding the trends shaping and driving the global Bronchopulmonary Dysplasia market
• Quantify patient populations in the global Bronchopulmonary Dysplasia market to improve product design, pricing, and launch plans
• Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Bronchopulmonary Dysplasia therapeutics in each of the markets covered
• Understand the magnitude of Bronchopulmonary Dysplasia population by its epidemiology
• The Bronchopulmonary Dysplasia Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

Key Assessments

• Patient Segmentation
• Disease Risk & Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population

Contents

1. KEY INSIGHTS

2. EXECUTIVE SUMMARY OF BRONCHOPULMONARY DYSPLASIA

3. BRONCHOPULMONARY DYSPLASIA: DISEASE BACKGROUND AND OVERVIEW

3.1. Introduction
3.2. Sign and Symptoms
3.3. Pathophysiology
3.4. Risk Factors
3.5. Diagnosis

4. PATIENT JOURNEY

5. EPIDEMIOLOGY AND PATIENT POPULATION

5.1. Epidemiology Key Findings
5.2. Assumptions and Rationale: 7MM
5.3. Epidemiology Scenario: 7MM
  5.3.1. Bronchopulmonary Dysplasia Epidemiology Scenario in the 7MM (2019- 2032)
5.4. United States Epidemiology
  5.4.1. Bronchopulmonary Dysplasia Epidemiology Scenario in the United States (2019- 2032)
5.5. EU-5 Country-wise Epidemiology
  5.5.1. Germany Epidemiology
    5.5.1.1. Bronchopulmonary Dysplasia Epidemiology Scenario in Germany (2019- 2032)
  5.5.2. France Epidemiology
    5.5.2.1. Bronchopulmonary Dysplasia Epidemiology Scenario in France (2019- 2032)
  5.5.3. Italy Epidemiology
    5.5.3.1. Bronchopulmonary Dysplasia Epidemiology Scenario in Italy (2019- 2032)
  5.5.4. Spain Epidemiology
    5.5.4.1. Bronchopulmonary Dysplasia Epidemiology Scenario in Spain (2019- 2032)
  5.5.5. United Kingdom Epidemiology
    5.5.5.1. Bronchopulmonary Dysplasia Epidemiology Scenario in the United Kingdom (2019-2032)
5.6. Japan Epidemiology
  5.6.1. Bronchopulmonary Dysplasia Epidemiology Scenario in Japan (2019- 2032)

6. TREATMENT ALGORITHM, CURRENT TREATMENT, AND MEDICAL PRACTICES

6.1. Bronchopulmonary Dysplasia Treatment and Management
6.2. Bronchopulmonary Dysplasia Treatment Algorithm

7. KOL VIEWS

8. UNMET NEEDS

9. APPENDIX

9.1. Bibliography
9.2. Report Methodology

10. DELVEINSIGHT CAPABILITIES

11. DISCLAIMER

12. ABOUT DELVEINSIGHT

*The table of contents is not exhaustive; will be provided in the final report

List Of Tables

LIST OF TABLES

List of Table:
Table 1: Bronchopulmonary Dysplasia Epidemiology in 7MM (2019-2032)
Table 2: Bronchopulmonary Dysplasia Diagnosed and Treatable Cases in 7MM (2019-2032)
Table 3: Bronchopulmonary Dysplasia Epidemiology in the United States (2019-2032)
Table 4: Bronchopulmonary Dysplasia Diagnosed and Treatable Cases in the United States (2019-2032)
Table 5: Bronchopulmonary Dysplasia Epidemiology in Germany (2019-2032)
Table 6: Bronchopulmonary Dysplasia Diagnosed and Treatable Cases in Germany (2019-2032)
Table 7: Bronchopulmonary Dysplasia Epidemiology in France (2019-2032)
Table 8: Bronchopulmonary Dysplasia Diagnosed and Treatable Cases in France (2019-2032)
Table 9: Bronchopulmonary Dysplasia Epidemiology in Italy (2019-2032)
Table 10: Bronchopulmonary Dysplasia Diagnosed and Treatable Cases in Italy (2019-2032)
Table 11: Bronchopulmonary Dysplasia Epidemiology in Spain (2019-2032)
Table 12: Bronchopulmonary Dysplasia Diagnosed and Treatable Cases in Spain (2019-2032)
Table 13: Bronchopulmonary Dysplasia Epidemiology in the United Kingdom (2019-2032)
Table 14: Bronchopulmonary Dysplasia Diagnosed and Treatable Cases in the United Kingdom (2019-2032)
Table 15: Bronchopulmonary Dysplasia Epidemiology in Japan (2019-2032)
Table 16: Bronchopulmonary Dysplasia Diagnosed and Treatable Cases in Japan (2019-2032)

List Of Figures

LIST OF FIGURES

List of Figures
Figure 1 Bronchopulmonary Dysplasia Epidemiology in 7MM (2019-2032)
Figure 2 Bronchopulmonary Dysplasia Diagnosed and Treatable Cases in 7MM (2019-2032)
Figure 3 Bronchopulmonary Dysplasia Epidemiology in the United States (2019-2032)
Figure 4 Bronchopulmonary Dysplasia Diagnosed and Treatable Cases in the United States (2019-2032)
Figure 5 Bronchopulmonary Dysplasia Epidemiology in Germany (2019-2032)
Figure 6 Bronchopulmonary Dysplasia Diagnosed and Treatable Cases in Germany (2019-2032)
Figure 7 Bronchopulmonary Dysplasia Epidemiology in France (2019-2032)
Figure 8 Bronchopulmonary Dysplasia Diagnosed and Treatable Cases in France (2019-2032)
Figure 9 Bronchopulmonary Dysplasia Epidemiology in Italy (2019-2032)
Figure 10 Bronchopulmonary Dysplasia Diagnosed and Treatable Cases in Italy (2019-2032)
Figure 11 Bronchopulmonary Dysplasia Epidemiology in Spain (2019-2032)
Figure 12 Bronchopulmonary Dysplasia Diagnosed and Treatable Cases in Spain (2019-2032)
Figure 13 Bronchopulmonary Dysplasia Epidemiology in the United Kingdom (2019-2032)
Figure 14 Bronchopulmonary Dysplasia Diagnosed and Treatable Cases in the United Kingdom (2019-2032)
Figure 15 Bronchopulmonary Dysplasia Epidemiology in Japan (2019-2032)
Figure 16 Bronchopulmonary Dysplasia Diagnosed and Treatable Cases in Japan (2019-2032)
*The table of contents is not exhaustive; will be provided in the final report